Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.

 Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G.
                             Xanthopoulos, Ph.D.

PR Newswire

FREMONT, Calif., April 15, 2013

FREMONT, Calif., April 15, 2013 /PRNewswire/ --Zosano Pharma, Inc., a
privately held pharmaceutical company developing products based on its novel
transdermal delivery technology, announced today the appointment of Kleanthis
G. Xanthopoulos, Ph.D., to its Board of Directors. Dr. Xanthopoulos is
President & Chief Executive Officer of Regulus Therapeutics Inc. (NASDAQ:
RGLS), a leading company developing microRNA therapeutics.

"I am pleased to welcome Dr. Xanthopoulos as our independent board member,"
said Vikram Lamba, Chief Executive Officer of Zosano Pharma. "He is a veteran
life sciences industry CEO whose extensive healthcare, execution and IPO
experience will provide Zosano with valuable insight as we pursue potential
public options for financing our extensive clinical development program."

Prior to joining Regulus in 2007, Dr. Xanthopoulos was a managing director of
Enterprise Partners Venture Capital. He co-founded and served as President and
Chief Executive Officer of Anadys Pharmaceuticals, and remained a Director
until its acquisition by Roche. He was Vice President at Aurora Biosciences
(acquired by Vertex Pharmaceuticals), and participated in The Human Genome
Project as a Section Head of the National Human Genome Research Institute.
Previously, he was an Associate Professor at the Karolinska Institute,
Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The
Rockefeller University, New York. An Onassis Foundation scholar, Dr.
Xanthopoulos received his B.Sc. in Biology with honors from Aristotle
University of Thessaloniki, Greece, and received both his M.Sc. in
Microbiology and Ph.D. in Molecular Biology from the University of Stockholm,
Sweden. Dr. Xanthopoulos is a member of the Board of Directors of the
Biotechnology Industry Organization (BIO), Apricus Biosciences, Sente Inc.,
and a member of the board of BIOCOM, Southern California's life science
industry association.

"I am delighted to join the Zosano Board," said Dr. Xanthopoulos. "Zosano's ZP
Patch Technology has the potential to provide novel drug delivery solutions
for many therapeutic indications – and I look forward to working with the
other Board members and management team to shape the company's future."

About Zosano Pharma

Zosano Pharma, Inc. is a private biopharmaceutical company and a pioneer in
the field of drug delivery systems. Zosano is developing products using ZP
Patch Technology, a novel transdermal delivery technology based on
microprojections that provide rapid and efficient systemic delivery in a
convenient, needle–free, and pain–free system. Zosano is a fully integrated
development company with a recently launched cGMP manufacturing capability.
The company is developing products with significant commercial potential both
independently and in collaboration with strategic partners. Learn more at
http://www.zosanopharma.com.







SOURCE Zosano Pharma, Inc.

Website: http://www.zosanopharma.com/
Contact: Jamie Lacey-Moreira, jamielacey@presscommpr.com, 410-299-3310
 
Press spacebar to pause and continue. Press esc to stop.